Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type.

Nakayama R, Mitani S, Nakagawa T, Hasegawa T, Kawai A, Morioka H, Yabe H, Toyama Y, Ogose A, Toguchida J, Nakayama T, Yoshida T, Ichikawa H.

Am J Surg Pathol. 2010 Nov;34(11):1599-607. doi: 10.1097/PAS.0b013e3181f7ce2c.

PMID:
20975339
2.

Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features.

van de Rijn M, Barr FG, Xiong QB, Hedges M, Shipley J, Fisher C.

Am J Surg Pathol. 1999 Jan;23(1):106-12.

PMID:
9888710
3.

Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases.

Pelmus M, Guillou L, Hostein I, Sierankowski G, Lussan C, Coindre JM.

Am J Surg Pathol. 2002 Nov;26(11):1434-40.

PMID:
12409719
4.

Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.

Izumi T, Oda Y, Hasegawa T, Nakanishi Y, Kawai A, Sonobe H, Takahira T, Kobayashi C, Yamamoto H, Tamiya S, Hirohashi S, Iwamoto Y, Tsuneyoshi M.

Am J Surg Pathol. 2007 Jan;31(1):85-94.

PMID:
17197923
5.

Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma.

Antonescu CR, Kawai A, Leung DH, Lonardo F, Woodruff JM, Healey JH, Ladanyi M.

Diagn Mol Pathol. 2000 Mar;9(1):1-8.

PMID:
10718206
6.

Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma.

Amary MF, Berisha F, Bernardi Fdel C, Herbert A, James M, Reis-Filho JS, Fisher C, Nicholson AG, Tirabosco R, Diss TC, Flanagan AM.

Mod Pathol. 2007 Apr;20(4):482-96. Epub 2007 Mar 2.

7.

Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray.

Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N, Kusuzaki K, Nakayama T, Tsuboyama T, Nakamura T, Imamura M, Nakamura Y, Toguchida J.

Cancer Res. 2002 Oct 15;62(20):5859-66.

8.

DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.

Kresse SH, Skårn M, Ohnstad HO, Namløs HM, Bjerkehagen B, Myklebost O, Meza-Zepeda LA.

Mol Cancer. 2008 Jun 3;7:48. doi: 10.1186/1476-4598-7-48.

9.

E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features.

Saito T, Oda Y, Sugimachi K, Kawaguchi K, Tamiya S, Tanaka K, Matsuda S, Sakamoto A, Iwamoto Y, Tsuneyoshi M.

Am J Pathol. 2001 Dec;159(6):2117-24.

10.

TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies.

Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, Downs-Kelly E, Corless CL, Rubin BP, van de Rijn M, Ladanyi M, Nielsen TO.

Am J Surg Pathol. 2007 Feb;31(2):240-6.

PMID:
17255769
11.
12.

Identification of altered MicroRNA expression patterns in synovial sarcoma.

Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, Akiyama H, Kondo S, Hashimoto H.

Genes Chromosomes Cancer. 2011 Mar;50(3):137-45. doi: 10.1002/gcc.20837. Epub 2010 Dec 7.

PMID:
21213367
13.

SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.

Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M.

N Engl J Med. 1998 Jan 15;338(3):153-60.

14.

Low expression of p27(Kip1), a cyclin-dependent kinase inhibitor, is a marker of poor prognosis in synovial sarcoma.

Kawauchi S, Goto Y, Liu XP, Furuya T, Oga A, Oda Y, Tsuneyoshi M, Ihara K, Sasaki K.

Cancer. 2001 Mar 1;91(5):1005-12.

PMID:
11251953
15.

Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma.

Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO.

Am J Surg Pathol. 2009 Dec;33(12):1743-51. doi: 10.1097/PAS.0b013e3181b7ed36.

PMID:
19809272
16.

Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.

Schaefer KL, Brachwitz K, Wai DH, Braun Y, Diallo R, Korsching E, Eisenacher M, Voss R, Van Valen F, Baer C, Selle B, Spahn L, Liao SK, Lee KA, Hogendoorn PC, Reifenberger G, Gabbert HE, Poremba C.

Cancer Res. 2004 May 15;64(10):3395-405.

17.

Diagnosis of synovial sarcoma with the reverse transcriptase-polymerase chain reaction: analyses of 84 soft tissue and bone tumors.

Hiraga H, Nojima T, Abe S, Sawa H, Yamashiro K, Yamawaki S, Kaneda K, Nagashima K.

Diagn Mol Pathol. 1998 Apr;7(2):102-10.

PMID:
9785009
18.
19.

Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma.

Nakayama R, Nemoto T, Takahashi H, Ohta T, Kawai A, Seki K, Yoshida T, Toyama Y, Ichikawa H, Hasegawa T.

Mod Pathol. 2007 Jul;20(7):749-59. Epub 2007 Apr 27.

20.

Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma.

Nuciforo PG, Pellegrini C, Fasani R, Maggioni M, Coggi G, Parafioriti A, Bosari S.

Hum Pathol. 2003 Jul;34(7):639-45.

PMID:
12874758

Supplemental Content

Support Center